↓ Skip to main content

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

Overview of attention for article published in F1000 Research, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
11 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry
Published in
F1000 Research, January 2015
DOI 10.12688/f1000research.6085.1
Pubmed ID
Authors

Jason Long, Edward Wright, Eleonora Molesti, Nigel Temperton, Wendy Barclay

Abstract

Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs. The former was the only available intervention when the current unprecedented Ebolavirus (EBOV) outbreak in West Africa began. Prior to this, the development of EBOV vaccines and anti-viral therapies required time and resources that were not available. Therefore, focus has turned to re-purposing of existing, licenced medicines that may limit the morbidity and mortality rates of EBOV and could be used immediately. Here we test three such medicines and measure their ability to inhibit pseudotype viruses (PVs) of two EBOV species, Marburg virus (MARV) and avian influenza H5 (FLU-H5). We confirm the ability of chloroquine (CQ) to inhibit viral entry in a pH specific manner. The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo. We propose CQ as a priority candidate to consider for treatment of EBOV.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 4%
Unknown 25 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 27%
Student > Master 5 19%
Student > Doctoral Student 2 8%
Other 2 8%
Student > Ph. D. Student 2 8%
Other 4 15%
Unknown 4 15%
Readers by discipline Count As %
Chemistry 7 27%
Agricultural and Biological Sciences 7 27%
Immunology and Microbiology 3 12%
Medicine and Dentistry 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Other 1 4%
Unknown 4 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2015.
All research outputs
#3,015,296
of 15,779,936 outputs
Outputs from F1000 Research
#1,312
of 4,104 outputs
Outputs of similar age
#55,655
of 289,354 outputs
Outputs of similar age from F1000 Research
#37
of 74 outputs
Altmetric has tracked 15,779,936 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,104 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.